The U.S. Food and Drug Administration has reported that they have approved Descovy (emtricitabine 200 mg and tenofovir alafenamide 25 mg) in at-risk adults and adolescents weighing at least 35kg for HIV-1 pre-exposure prophylaxis (PrEP) who at at risk of acquiring HIV.
The Epidemiological Impact and Cost-effectiveness of Key Population-led PrEP Delivery to Prevent HIV among Men who Have Sex with Men in Thailand: A modelling study
This article from The Lancet Southeast Asia discusses the results of a study to determine the epidemiological impact and cost-effectiveness of key population-led PrEP service delivery.
Application of Bayesian Networks to Identify Factors Influencing Acceptability of HIV Pre-exposure Prophylaxis in Guilin, China
This article from Scientific Reports presents the results of a cross-sectional survey conducted in Guilin, China among female sex workers, people who inject drugs, and men who have sex with men to assess the acceptability of PrEP and related influencing factors.
Characterizing the Impact of the COVID-19 Pandemic on HIV PrEP care: A review and synthesis of the literature
This review from the journal AIDS and Behavior provides an examination of the influences of the COVID-19 pandemic on engagement in the PrEP care continuum, and looks at the barriers and facilitators to PrEP uptake during this time.
Mapping Implementation Science with Expert Recommendations for Implementing Change (MIS-ERIC): Strategies to Improve PrEP Use among Black Cisgender Women Living in Mississippi
This article from the Journal of Racial and Ethnic Health Disparities describes an analysis of qualitative interviews undertaken in Mississippi, USA with Black, cisgender women at risk for HIV and community healthcare clinic staff who work directly with this population in order to identify barriers to PrEP uptake and select appropriate implementation strategies to increase…
A Qualitative Exploration of New and Existing HIV PrEP Modalities Among Men Who Have Sex with Men in Philadelphia
This article from Open Forum Infectious Diseases explores the treatment characteristics that may influence the willingness and uptake of long-acting injectable PrEP as opposed to the daily pills among a racially diverse sample of gay and bisexual men who have sex with men in Philadelphia, Pennsylvania, USA.
Uptake of and Adherence to Oral Pre-exposure Prophylaxis among Adolescent Girls and Young Women at High Risk of HIV-Infection in Kampala, Uganda: A qualitative study of experiences, facilitators and barriers
This article from BMC Women’s Health describes the results of a qualitative study exploring the experiences, facilitators and barriers of PrEP uptake and adherence to PrEP among adolescent girls and young women in Kampala, Uganda.
Self-reported and Pill Count Measures of Adherence to Oral HIV PrEP among Female Sex Workers Living in South-Western Uganda
This article from PLOS One reports on a study evaluating PrEP adherence amongst female sex workers in southwestern Uganda using clinic-based pill counts and self-reported measures, and examines factors associated with protective levels of adherence.
Initial Implementation of HIV PrEP for People who are Incarcerated in Zambia: A cross-sectional observational study
This article from The Lancet HIV describes a cross-sectional observational study of a PrEP programme implemented between October 2020 and March 2021 in 16 criminal justice facilities in four Zambian provinces.
Prevalence of HIV PrEP Prescribing Among Persons With Commercial Insurance and Likely Injection Drug Use
This article from the Journal of the American Medical Association (JAMA) estimates HIV PrEP uptake among commercially insured persons with opioid or stimulant use disorder by injection drug use status in the USA.
Results from a Safety Study of the Dapivirine Vaginal Ring and Oral PrEP in Breastfeeding Mother-Infant Pairs
This poster from AIDS 2022 presents results from the MTN-043/B-Protected trial, comparing the safety profile of the dapivirine vaginal ring against oral PrEP use during breastfeeding.